Gyre Therapeutics (GYRE) has released an update.
GNI Group Ltd. released its financial results for the year ended December 31, 2023, on February 14, 2024, spotlighting the performance of its subsidiary, Gyre Therapeutics. The report also highlighted key future events, including the expected submission of an Investigational New Drug application and the completion of Phase 3 clinical trials for Hydronidone in China. Additionally, Gyre Therapeutics settled legal disputes regarding its business combination agreement by agreeing to pay attorney’s fees, thereby avoiding further litigation costs.
For further insights into GYRE stock, check out TipRanks’ Stock Analysis page.
